Physician profile
Stephanos Rizos
NPI 1376515841
$560.92
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $58.53 · 2021: $97.44 · 2022: $77.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.44 | 2019-2020 | |
| Hologic Sales and Service, LLC | $97.44 | 2021 | |
| Novo Nordisk INC | $79.32 | 2019-2020 | |
| Pfizer INC. | $36.39 | 2022 | |
| Therapeuticsmd, INC. | $33.67 | 2019 | |
| Amgen INC. | $27.64 | 2019 | |
| Astellas Pharma US INC | $22.40 | 2019 | |
| Avion Pharmaceuticals | $22.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.61 | 2019 | |
| Myovant Sciences INC. | $18.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.54 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanos Rizos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.